The DOI matches its Crossref record.
Effects of Venlafaxine on Blood Pressure: A Meta-Analysis of Original Data From 3744 Depressed Patients
Abstract
BACKGROUND: Venlafaxine hydrochloride, a structurally novel antidepressant, is also the first nontricyclic serotonin/norepinephrine reuptake inhibitor. Although venlafaxine has an overall side effect and safety profile that is comparable to other newer antidepressants, it can cause both transient and sustained elevations of supine diastolic blood pressure (SDBP), probably the result of noradrenergic potentiation. METHOD: Presented here is a meta-analysis of original data on blood pressure, using both random effects and a multivariate survival analyses. The sample consisted of 3744 patients with major depression who were studied in controlled clinical trials comparing venlafaxine with imipramine and/or placebo. Patients were treated for 6 weeks of acute phase therapy; some responders received up to 1 year of continuation phase therapy. RESULTS: Venlafaxine and imipramine were associated with small, but statistically significant, increases in SDBP during acute phase therapy. When compared with imipramine and placebo, venlafaxine was also associated with a greater proportion of persistent elevations of SDBP during continuation therapy. The effect of venlafaxine was highly dose dependent, and the incidence of elevated SDBP was statistically and clinically significant only at dosages above 300 mg/day. Venlafaxine did not adversely affect the control of blood pressure for patients with preexisting high blood pressure or elevated baseline values. CONCLUSION: Venlafaxine has a dose-dependent effect on SDBP that is clinically significant at high dosages. Concern about blood pressure effects should not deter first-line use of this effective antidepressant, although more extensive studies of patients with cardiovascular diseases are still necessary.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Likewise, dose-dependent increases in BP have been reported in patients receiving therapeutic doses of venlafaxine.247”
From Resistant Hypertension: Detection, Evaluation, and Management: A Scientific Statement From the American Heart Association (2018) · cites this paper as [247]
Citations
Cited by
Sorted by citations
Items 201–300 of 332
Osser, D. N., Renner, J. A., & Bayog, R. D. (1999) · Psychiatric Annals · doi:10.3928/0048-5713-19990501-10 · Cited by 11
Monoaminergic‐based Pharmacotherapy for Depression
Papakostas, G. I., & D, M. F. M. (2005) · Wiley eBooks · doi:10.1002/9783527619672.ch6 · Cited by 11
Balachander, S., Kodancha, P. G., Arumugham, S. S., Sekharan, J. T., Narayanaswamy, J. C., & Reddy, Y. C. J. (2018) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000000989 · Cited by 10
Thase, M. E., Fayyad, R. S., Cheng, R.-F. J., Guico‐Pabia, C. J., Sporn, J., Boucher, M., & Tourian, K. A. (2015) · Current Medical Research and Opinion · doi:10.1185/03007995.2015.1020365 · Cited by 10
Self-citationDrugs that increase blood pressure
Sander, G. E. (2011) · Therapy · doi:10.2217/thy.11.25 · Cited by 10
Selective Serotonin Reuptake Inhibitors and Intraoperative Blood Pressure
van Haelst, I. M. M., van Klei, W. A., Doodeman, H. J., Kalkman, C. J., & Egberts, T. C. G. (2011) · American Journal of Hypertension · doi:10.1038/ajh.2011.194 · Cited by 10
Identifying and Managing Factors that Interfere with or Worsen Blood Pressure Control
Basile, J., & Bloch, M. J. (2010) · Postgraduate Medicine · doi:10.3810/pgm.2010.03.2120 · Cited by 11
Therapeutic options: Addressing the current dilemma
Dinan, T. G. (2006) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2006.04.004 · Cited by 11
Tolerability of Amine Uptake Inhibitors in Urologic Diseases
Michel, M. C., Ruhé, H. G., de Groot, A. A., Castro, R. S., & Oelke, M. (2006) · Current Drug Safety · doi:10.2174/157488606775252601 · Cited by 10
Colosimo, F. A., Borsellino, P., Krider, R. I., Márquez, R., & Vida, T. A. (2024) · Psychoactives · doi:10.3390/psychoactives3010007 · Cited by 11
“Additionally, SNRIs have a similar side effect profile with the added risk of clinically significant supine diastolic blood pressure increase [146].”
BackgroundDesvenlafaxine-Induced Worsening of Hypertension
Munoli, R. N., Praharaj, S. K., Bhandary, R. P., et al. (2013) · Journal of Neuropsychiatry · doi:10.1176/appi.neuropsych.12030074 · Cited by 9
Depression in vascular pathologies: the neurologist's point of view
Moretti, R., Bernobich, E., Francesca, E., Torre, P., Rodolfo, A., Angelis, L. D., & Bellini, G. (2011) · Vascular Health and Risk Management · doi:10.2147/vhrm.s20147 · Cited by 9
Chugh, P. K., Kalra, B. S., Kaushik, N., & Tekur, U. (2013) · Europe PMC (PubMed Central) · Cited by 9
Centrally Targeted Pharmacotherapy for Chronic Abdominal Pain: Understanding and Management
Törnblom, H., & Drossman, D. A. (2016) · Handbook of experimental pharmacology · doi:10.1007/164_2016_106 · Cited by 9
Medical Complications of Psychiatric Treatment
Lahijani, S. C., & Harris, K. A. (2017) · Critical Care Clinics · doi:10.1016/j.ccc.2017.03.008 · Cited by 8
“Statistically and clinically significant elevations in blood pressure persist during treatment with high doses of venlafaxine(39); however, treatment with venlafaxine does not complicate control of blood pressure in patients with preexisting hypertension.(39) Sustained hypertension has not been observed in studies of…”
BackgroundFrom Efficacy to Adversity: Understanding the Side Effects of Antidepressants - systematic review
Hrabar, V., Studeniak, T., Pryima, M., & Kondratskyi, V. (2025) · Wiadomości Lekarskie · doi:10.36740/wlek/197143 · Cited by 10
“Venlafaxine has potentially the most unfavorable profile in this group of effects, requires constant blood pressure monitoring and should be used with caution in patients with hypertension [36].”
Koslow, S. H., Ruiz, P., & Nemeroff, C. B. (2014) · Cambridge University Press eBooks · doi:10.1017/cbo9781139519502.028 · Cited by 8
Second-Generation Antidepressants in the Pharmacologic Treatment of Adult Depression
Gartlehner, G., Hansen, R. A., Morgan, L. C., Thaler, K. J., Lux, L. J., Noord, M. V., Mager, U., Gaynes, B. N., Thieda, P., Strobelberger, M., et al. (2011) · Cited by 8
DULOXETINE- INDUCED HYPERTENSION: A CASE REPORT
Mermi, O., & Atmaca, M. (2015) · Turkish Journal of Psychiatry · doi:10.5080/u10168 · Cited by 9
“In another study stated that there is an increase in blood pressure only in 3% of the patients using a normal dose (75-150 mg) of venlafaxine of the long oscillation formulation (Thase 1998).”
BackgroundInfluentialHorner syndrome in fibromuscular dysplasia without carotid dissection
McInnis, C. P., Haynor, D. R., & Francis, C. E. (2016) · Canadian Journal of Ophthalmology · doi:10.1016/j.jcjo.2015.10.019 · Cited by 8
Jennings, L. (2018) · Springer eBooks · doi:10.1007/978-3-319-74604-3_4 · Cited by 12
A Severe Adverse Effect of Atomoxetine: Hypertensive Crisis
Güldiken, G., & Karayağmurlu, A. (2020) · Clinical Neuropharmacology · doi:10.1097/wnf.0000000000000380 · Cited by 7
“Other causes of HT may include withdrawal from antihypertensive medications, such as clonidine or β-adrenergic blockers; substance abuse, such as cocaine or amphetamines; medications, such as oral contraceptive pills, corticosteroids, decongestants, ephedrine, or pseudoephedrine; and seratonin and norepinephrine (nora…”
BackgroundEfficacy of Noradrenergic-Selective Agents in the Treatment of Neuropsychiatric Diseases
Kasper, S. F., & Resinger, E. (2001) · CNS Spectrums · doi:10.1017/s1092852900001413 · Cited by 6
(1997) · Annals of Pharmacotherapy · doi:10.1177/106002809703100720 · Cited by 7
Contemporary Concepts in the Pharmacotherapy of Depression in Older People
Rojas‐Fernandez, C. H., & Mikhail, M. (2012) · Canadian Pharmacists Journal / Revue des Pharmaciens du Canada · doi:10.3821/145.3.cpj128 · Cited by 6
Findling, R. L., Groark, J., Tourian, K. A., Ramaker, S., Chiles, D., Yang, L., & Nichols, A. I. (2016) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2016.0009 · Cited by 6
“…of sustained elevation in diastolic blood pressure ( ‡ 90 mm Hg) was associated with venlafaxine at high doses ( > 300 mg/day) only (Feighner 1995; Thase 1998); however, the U.S. FDA prescribing information recommends regular or periodic blood pressure monitoring throughout treatment for adult…”
Depression as a risk factor for cardiac illness – What do we know about?
Padhy, S. K., Sarkar, S., Davuluri, T., & Malhotra, N. (2015) · Journal of Indian College of Cardiology · doi:10.1016/j.jicc.2015.02.004 · Cited by 6
Desai, R. A., Park, H., Brown, J. D., Mohandas, R., & Smith, S. M. (2022) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.2686 · Cited by 6
“x) in the 12- month baseline period; (2) no recent modification of current antihypertensive regimen, defined as no addition or discontinuation of antihypertensive therapy or change in dose for at least 60 days prior to the index date.”
BackgroundMethodResultInfluentialDyer, A. H., Murphy, C., Briggs, R., LAWLOR, B. A., Kennelly, S., & for the NILVAD Study Group (2020) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.5377 · Cited by 6
Review of Duloxetine and Venlafaxine in Depression
Zerjav-Lacombe, S., Tse, G., & Scott, M. J. W. (2009) · Canadian Pharmacists Journal / Revue des Pharmaciens du Canada · doi:10.3821/1913-701x-142.3.144 · Cited by 9
[Psychological disorders and cardiovascular diseases].
Monami, M., & Marchionni, N. (2007) · PubMed · Cited by 6
Comparison of Tolerance of Venlafaxine, Paroxetine and Amitriptyline in Depression Therapy
Miskovic, M. (2015) · Medical Archives · doi:10.5455/medarh.2015.69.107-109 · Cited by 5
“Side effects of venlafaxine: gastrointestinal effects, activation/ insomnia, sexual side effects as well as rise in arterial pressure (11).”
BackgroundKasper, S. F. (2019) · International Journal of Psychiatry in Clinical Practice · doi:10.1080/13651501.2018.1519080 · Cited by 5
“The effect of venlafaxine was dose dependent, with clinically significant increase in BP for dosages above 300mg/day (Thase, 1998; Zimmer et al., 1997).”
BackgroundBreeden, M. A., Gillis, A., Salas, J., & Scherrer, J. F. (2021) · Journal of Psychosomatic Research · doi:10.1016/j.jpsychores.2021.110692 · Cited by 5
Diksha, Singh, L., & Bhatia, D. (2023) · Metabolic Brain Disease · doi:10.1007/s11011-023-01302-7 · Cited by 6
“Venlafaxine, for example, causes hypertension (Dose more than 300 mg/kg) (Thase 1998) and sexual dysfunction.”
Tang, N. K. Y., Goodchild, C. E., & Webster, L. R. (2014) · Springer eBooks · doi:10.1007/978-1-4939-1821-8_16 · Cited by 7
Safety and Tolerability of Extended-Release Venlafaxine in Severe Medical and Surgical Illness
Schwartz, T. L., Jindal, S., Virk, S., et al. (2004) · Psychosomatics · doi:10.1176/appi.psy.45.3.217 · Cited by 5
Pharmacologic Strategies for Treatment-resistant Depression: An Update on the State of the Evidence
Thase, M. E. (2005) · Psychiatric Annals · doi:10.3928/00485713-20051201-04 · Cited by 5
Self-citationMicrobial bionic nano-aromatic drugs for prevention of depression induced by chronic stress
Liu, R., Zhang, T., Bai, C., Chen, J., Zhang, X., Liu, G., Shen, S., Yuan, J., & Lü, Z. (2024) · Journal of Nanobiotechnology · doi:10.1186/s12951-024-02382-y · Cited by 4
Tang, N. K. Y., Goodchild, C. E., & Webster, L. R. (2012) · Springer eBooks · doi:10.1007/978-1-4614-1560-2_85 · Cited by 4
Drug Class Review on Second Generation Antidepressants: Final Report
Gartlehner, G., Hansen, R. A., Kahwati, L. C., Lohr, K. N., Gaynes, B. N., & Carey, T. (2006) · Cited by 5
Hofferer, A., Dolladille, C., Chrétien, B., Sassier, M., Laugier, D., Atzenhoffer, M., Bagheri, H., Alexandre, J., Fédrizzi, S., & Humbert, X. (2021) · L Encéphale · doi:10.1016/j.encep.2021.04.009 · Cited by 4
Even Low-Dose Treatment of Venlafaxine May Provoke Recurrence of Hypertension in An Asian Patient?
Bahk, W., Pae, C., Chae, J., et al. (2001) · General Hospital Psychiatry · doi:10.1016/s0163-8343(01)00143-8 · Cited by 4
Epidemiologie und Therapie depressiver Störungen/ Epidemiology and treatment of depressive disorders
Linden, M. (2003) · Zeitschrift für psychosomatische Medizin und Psychotherapie · doi:10.13109/zptm.2003.49.4.333 · Cited by 4
Antidepressant combinations: epidemiological considerations
Agüera, L., Rojo, E., Ros, S., et al. (2005) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.2005.00674.x · Cited by 4
Leivaditis, V., Mulita, F., Andrikopoulou, C., Shaska, E., Liolis, E., Mitsos, S., Grapatsas, K., Tomos, P., & Baikoussis, N. G. (2026) · Medical Sciences · doi:10.3390/medsci14020244 · Cited by 3
“Evidence suggests that venlafaxine is associated with dose-dependent increases in blood pressure and requires careful monitoring in cardiovascular populations [77].”
Granata, L. G., Giubilato, S., Giuffrida, C., Pavan, D., Mojoli, M., Aspromonte, N., Fumarulo, I., Marchetta, M., Sbrigata, A., Pisano, C., et al. (2026) · Journal of Cardiovascular Development and Disease · doi:10.3390/jcdd13070301 · Cited by 3
“…(SNRIs), including venlafaxine and duloxetine, are generally considered acceptable alternatives; however, caution may be warranted in patients with poorly controlled hypertension or significant cardiovascular disease because of their potential to increase heart rate and blood pressure [139].”
Developing practical recommendations for drug-disease interactions in patients with hypertension
Özokcu, K., Diesveld, M. M. E., Gipmans, S. G. H., Peeters, L. E. J., van den Born, B. H., & Borgsteede, S. D. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1360146 · Cited by 7
Alosaimi, F. D., & Baker, B. (2012) · Saudi Medical Journal · doi:10.15537/1658-3175.5648 · Cited by 3
Trends and Outcomes of Coronary Artery Bypass Grafting in Patients with Major Depressive Disorder
Re, A. M. D., Perla, K. M. R., Aghagoli, G., Bellam, K. G., Sellke, F. W., & Ehsan, A. (2022) · Heart and Mind · doi:10.4103/hm.hm_62_21 · Cited by 3
Diabetic Neuropathic Pain: Real World Treatment Options
Lindsay, T. J., Vitrikas, K., Temporal, M., & Herndon, C. M. (2012) · Clinical Medicine Insights Therapeutics · doi:10.4137/cmt.s7266 · Cited by 4
Venlafaxine-Induced Orthostatic Hypotension in a Geriatric Patient
Chikkaramanjegowda, V., & de León, J. (2013) · Case Reports in Psychiatry · doi:10.1155/2013/761567 · Cited by 3
“Articles focused on venlafaxine cardiovascular ADRs describe venlafaxine as being prone to cause hypertension, but it is not considered to cause orthostatic hypotension [4, 5].”
BackgroundSide Effects of Psychotropic Medications
Huffman, J. C., & Stern, T. A. (2008) · Elsevier eBooks · doi:10.1016/b978-0-323-04743-2.50053-6 · Cited by 4
Vance, A. L. A., Costin, J., & Maruff, P. T. (2002) · European Child & Adolescent Psychiatry · doi:10.1007/s007870200004 · Cited by 3
“Trends in Cognitive Sciences 2:436–446 5. Baker GB, Bornstein RA, Douglas AB, Van Muyden JC, Ashton S, Bazylewich TL (1993) Urinary excretion of MHPG and normetanephrine in attention deficit hyperactivity disorder. Molecular and Chemical Neuropathology 18:173–178 6. Biederman J, Faraone SV, Milberger S, Guite J, Mick…”
BackgroundInfluentialLaux, G., & Klimke, A. (2022) · Springer eBooks · doi:10.1007/978-3-030-62059-2_414 · Cited by 2
Treating hearts and minds: adverse cardiovascular effects of psychiatric medications
Raja, A., Leslie, S. J., Buist, E., Rushworth, G. F., Megson, I. L., & McNamara, N. (2026) · Therapeutic Advances in Drug Safety · doi:10.1177/20420986261418947 · Cited by 4
Venlafaxine and Desvenlafaxine
Thase, M. E., & Sloan, D. (2009) · American Psychiatric Association Publishing eBooks · doi:10.1176/appi.books.9781585623860.as22 · Cited by 2
Self-citationD, M. F. M., & Papakostas, G. I. (2008) · Elsevier eBooks · doi:10.1016/b978-0-323-04743-2.50045-7 · Cited by 2
Hu, S., Chen, K., Xu, Q., Wang, F., & Na, W.-Q. (2024) · General Hospital Psychiatry · doi:10.1016/j.genhosppsych.2024.09.001 · Cited by 3
The Effect of Antidepressant Therapy on Blood Pressure and Heart Rate Variability
Myers, A. K., & Trivedi, M. H. (2013) · Psychopharm Review · doi:10.1097/01.psyphr.0000425505.76789.f1 · Cited by 2
Drug-induced systemic hypertension
Coleman, J. J., & Martin, U. (2006) · Adverse Drug Reaction Bulletin · doi:10.1097/01.fad.0000268335.14214.8b · Cited by 2
The Effects of Reboxetine and Venlafaxine on ECG Variables in Depressed Patients
Eker, S., Akkaya, C., Cangür, Ş., Yuvanç, U., Sarandöl, A., & Kırlı, S. (2011) · Psychiatry and Clinical Psychopharmacology · doi:10.5350/kpb-bcp201121103 · Cited by 2
Venlafaxine in divided doses – a case report
II Klinika Psychiatryczna, O. C. A., & Święcicki, Ł. (2015) · Psychiatria i Psychologia Kliniczna · doi:10.15557/pipk.2015.0007 · Cited by 2
Factors That Impact Choice of Antidepressant Treatment in Medically Complex Patients
Dago, P. L. (2009) · CNS Spectrums · doi:10.1017/s1092852900026377 · Cited by 2
Treatment of late-life generalized anxiety disorder
Papp, L. A., Gorenstein, E. E., & Mohlman, J. (2010) · Cambridge University Press eBooks · doi:10.1017/cbo9780511777578.028 · Cited by 2
The risk of a blood pressure increase during treatment with selected psychotropic drugs
Romańczyk, M., Surma, S., Kocyan, B., Kłos, K., Strona, W., & Krzystanek, M. (2022) · Arterial Hypertension · doi:10.5603/ah.a2021.0015 · Cited by 3
Linden, M. (2008) · Springer eBooks · doi:10.1007/3-540-32221-3_24 · Cited by 2
Ostroumova, O. D., Sychev, D. A., Кочетков, А. И., Оstroumova, Т. М., Kulikova, M., & De, V. A. (2022) · Medical alphabet · doi:10.33667/2078-5631-2022-3-8-13 · Cited by 2
Psychopharmacology for Pediatric Depressive Disorders
Rengasamy, M. L., Shalev, A., & Birmaher, B. B. (2024) · Springer eBooks · doi:10.1007/978-3-031-57472-6_16 · Cited by 2
Therapeutic Alternatives for Difficult-to-treat Depression: What is the State of the Evidence?
Thase, M. E. (2003) · Psychiatric Annals · doi:10.3928/0048-5713-20031201-08 · Cited by 2
Self-citationAntidepressant analgesics in the management of chronic pain
Gurba, K. N., & Haroutounian, S. (2022) · Wiley eBooks · doi:10.1002/9781119701170.ch16 · Cited by 2
Venlafaxine and antihypertensive drugs
Lam, Y. W. F. (2018) · The Brown University Psychopharmacology Update · doi:10.1002/pu.30368 · Cited by 1
Baldomero, E. B., Enguix, S. C., & Teseo, G. D. E. (2005) · Psiquiatría Biológica · Cited by 1
Survey of Venlafaxine prescriptions following the 2004 NICE guidelines on depression
Kinnair, D. J., & Bruce, J. (2007) · Clinical Governance An International Journal · doi:10.1108/14777270710775909 · Cited by 1
Concern About the Use of Venlafaxine to Treat Vasomotor Symptoms—Reply
Joffe, H., LaCroix, A. Z., & Cohen, L. S. (2015) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2014.7997 · Cited by 1
Laux, G., & Klimke, A. (2022) · Springer eBooks · doi:10.1007/978-3-319-56015-1_414-1 · Cited by 1
(2009) · Elsevier eBooks · doi:10.1016/b978-0-444-53266-4.50004-5 · Cited by 1
Medication for Depression: Monoamine Enhancers and Esketamine (Antidepressants)
Park, S., & Shen, W. W. (2023) · Springer eBooks · doi:10.1007/978-3-030-42825-9_133-1 · Cited by 4
Chapter 9. Augmentation Strategies for Treatment-Resistant Disorders
(2024) · American Psychiatric Association Publishing eBooks · doi:10.1176/appi.books.9798894551289.cd09 · Cited by 1
Side Effects of Psychotropic Medications
Onyeaka, H., Beach, S. R., Huffman, J. C., & Stern, T. A. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-11972-9.00013-2 · Cited by 1
Fi, B., Veltishchev, D. Y., Volel, B. A., Garganeeva, N. P., Kopylov, F. Y., Lareva, N. V., Medvedev, V. E., Mosolov, S. N., Petrova, M. M., Петрунько, О. В., et al. (2025) · Kardiologiia · doi:10.18087/cardio.2025.6.n2921 · Cited by 2
Management of major depressive disorder in primary care.
Dantz, B. (2008) · PubMed · Cited by 1
Delayed Sinus Tachycardia Associated With Venlafaxine Administration
Osuagwu, F. C., & Bradley, R. H. (2019) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000001140 · Cited by 1
Kaur, H., Sidana, A. K., & Singh, T. K. (2019) · Journal of Mental Health and Human Behaviour · doi:10.4103/jmhhb.jmhhb_21_19 · Cited by 1
Psychopharmacology in the Treatment of Patients with Cardiovascular Disease
Beach, S. R., Celano, C. M., Huffman, J. C., & Stern, T. A. (2016) · Springer eBooks · doi:10.1007/978-981-287-206-7_53 · Cited by 1
Effects of CYP2C9 and VKORC1 polymorphisms and drug interactions on coumarin anticoagulation control
Schalekamp, T. (2007) · Utrecht University Repository (Utrecht University) · Cited by 1
Pharmakotherapie der Depression bei Menschen mit Diabetes
Kahl, K. G., Lampen-Imkamp, S., Göllner, K., Liersch, J., Claaßen, B., Wilkening, A., Schik, G., & Peschel, T. (2010) · Der Diabetologe · doi:10.1007/s11428-009-0534-6 · Cited by 1
Cognitive-Behavioural Therapy Combined with Antidepressants for Major Depressive Disorder
Maneeton, N. (2012) · InTech eBooks · doi:10.5772/30340
“supine diastolic blood pressure (Thase, 1998).”
BackgroundTreatment of Psychiatric Disorders in HIV
Ferrara, M., Valero, I., Moore, D. J., Knight, A. F., Duarte, N. A., & Atkinson, J. H. (2014) · Wiley eBooks · doi:10.1002/9781118339503.ch4 · Cited by 1
Concern About the Use of Venlafaxine to Treat Vasomotor Symptoms
Zhou, S., Lun, Y., & Li, D. (2015) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2014.7988
Hearts Sing the Blues Too: Depression in Elderly Cardiac Patients
Darby, C. D. (2004) · Developments in cardiovascular medicine · doi:10.1007/978-1-4419-8865-2_3
Duloxetine in the management of depression
McAllister-Williams, H. (2006) · Future Neurology · doi:10.2217/14796708.1.6.713
“Regarding the toxicity of venlafaxine, at the present time there are no published data in the public domain demonstrating cardiotoxicity beyond information showing an association between the drug and small increases in blood pressure [9].”
BackgroundPSYCHOTROPIC INTERACTIONS OF SOME ANTI-HYPERTENSIVES IN MALE ALBINO RATS AND MICE
Vivek, V., & Pa, P. (2008)
Psychopharmacology in the Treatment of Patients with Cardiovascular Disease
Beach, S. R., Celano, C. M., Huffman, J. C., & Stern, T. A. (2015) · Springer eBooks · doi:10.1007/978-981-4560-53-5_53-1
Reikvam, A.-G. (2010) · NORA - Norwegian Open Research Archives
The use of venlafaxine at doses higher than 225 mg/day. The balance of risks and benefits
II Klinika Psychiatryczna, O. C. A., & Święcicki, Ł. (2014) · Psychiatria i Psychologia Kliniczna · doi:10.15557/pipk.2014.0030
Alıcı, H., Ercan, S., Alıcı, D., et al. (2014) · Angiology · doi:10.1177/0003319714535483
Ocampo, D., & Gemima, M. P. (2016)
Terada, T., Kitamura, N., & Nakanishi, T. (2016) · Palliative Care Research · doi:10.2512/jspm.11.553
β-Blockers in Diabetic Patients With Heart Failure
Bachhuber, M. A., Saloner, B. K., Barry, C. L., Wood, R. S., Davis, L. G., & Bloomberg, H. (2017)
Metadata
- Authors
- Thase, M. E.
- Affiliations
- University of Pittsburgh (US)
- Corresponding author
- Thase, Michael E.
- Venue
- The Journal of Clinical Psychiatry
- Publisher
- Physicians Postgraduate Press, Inc
- Published
- 1998-10-15
- Volume
- 59
- Issue
- 10
- Pages
- 502-508
- ISSN
- 0160-6689 (ISSN-L)
- OpenAlex
- W2074133854
- Cited by
- 331
- References
- 0
- Citations by year
- 2026: 7 · 2025: 6 · 2024: 14 · 2023: 3 · 2022: 11 · 2021: 6 · 2020: 7 · 2019: 16 · 2018: 11 · 2017: 9 · 2016: 13 · 2015: 15 · 2014: 14 · 2013: 10 · 2012: 12
- FWCI
- 4.64
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Clinical Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institute of Mental Health (MH30915)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Blood Pressure and Hypertension Studies
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac Health and Mental Health
- Keywords
- venlafaxine, blood pressure, serotonin-norepinephrine reuptake inhibitors, major depressive disorder, imipramine, dose dependence, antihypertensive effect, antidepressant side effects
- MeSH terms
- Venlafaxine Hydrochloride, Adult, Aged, Blood Pressure, Cyclohexanols, Depressive Disorder, Diastole, Dose-Response Relationship, Drug, Female, Humans, Hypertension, Male, Middle Aged, Posture, Regression Analysis, Incidence, Proportional Hazards Models, Antidepressive Agents, Second-Generation
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
